Kraig Biocraft Laboratories Prepares for Second BAM-1 Hybrid Spider Silk Production Harvest
Kraig Biocraft Laboratories (OTCQB: KBLB) announces the return of renowned sericulture expert Dr. Nirmal Kumar to oversee the completion of the second production cycle of BAM-1 spider silk hybrids. This cycle builds on the success of the first production completed in July 2024. Dr. Kumar will supervise cocoon production, monitor quality, and lead large-scale selective matings for a planned 10X capacity increase. The company aims to produce metric-ton level spider silk and solidify its position in cost-effective, eco-responsible spider silk production. CEO Kim Thompson states that 2024 is a breakout year for Kraig Labs, with ongoing expansion of BAM-1 production hybrids.
Kraig Biocraft Laboratories (OTCQB: KBLB) annuncia il ritorno del rinomato esperto di sericoltura, il Dr. Nirmal Kumar, per supervisionare il completamento del secondo ciclo di produzione degli ibridi di seta di ragno BAM-1. Questo ciclo si basa sul successo del primo ciclo di produzione, completato a luglio 2024. Il Dr. Kumar supervisionerà la produzione dei bozzoli, monitorerà la qualità e guiderà accoppiamenti selettivi su larga scala per un aumento della capacità pianificato di 10 volte. L'azienda punta a produrre seta di ragno a livello di tonnellate metriche e a consolidare la propria posizione nella produzione di seta di ragno economica e eco-responsabile. Il CEO Kim Thompson afferma che il 2024 è un anno di svolta per Kraig Labs, con una continua espansione della produzione degli ibridi BAM-1.
Kraig Biocraft Laboratories (OTCQB: KBLB) anuncia el regreso del renombrado experto en sericultura, el Dr. Nirmal Kumar, para supervisar la finalización del segundo ciclo de producción de híbridos de seda de araña BAM-1. Este ciclo se basa en el éxito del primer ciclo de producción, completado en julio de 2024. El Dr. Kumar supervisará la producción de capullos, controlará la calidad y llevará a cabo apareamientos selectivos a gran escala para un aumento planeado de la capacidad de 10 veces. La empresa tiene como objetivo producir seda de araña a nivel de toneladas métricas y consolidar su posición en la producción de seda de araña rentable y ecológica. El CEO Kim Thompson declara que 2024 es un año decisivo para Kraig Labs, con la expansión continua de la producción de híbridos BAM-1.
Kraig Biocraft Laboratories (OTCQB: KBLB)는 유명한 양잠 전문가인 닐말 쿠마르 박사가 BAM-1 거미실 하이브리드의 두 번째 생산 주기를 감독하기 위해 복귀했다고 발표했습니다. 이번 주기는 2024년 7월에 완료된 첫 번째 생산의 성공을 기반으로 하고 있습니다. 쿠마르 박사는 고치를 생산하고 품질을 모니터링하며 계획된 10배의 생산 능력 증가를 위해 대규모 선택적 교배를 이끌 것입니다. 이 회사는 미터 톤 수준의 거미 실크를 생산하고 비용 효율적이며 친환경적인 거미 실크 생산에서의 입지를 확립하는 것을 목표로 하고 있습니다. CEO 킴 톰슨은 2024년이 Kraig Labs의 전환점이 될 해이며 BAM-1 생산 하이브리드의 지속적인 확장을 말했습니다.
Kraig Biocraft Laboratories (OTCQB: KBLB) annonce le retour du célèbre expert en sériciculture, le Dr Nirmal Kumar, pour superviser l'achèvement du deuxième cycle de production des hybrides de soie d'araignée BAM-1. Ce cycle s'appuie sur le succès du premier cycle de production, achevé en juillet 2024. Le Dr Kumar supervisera la production des cocons, surveillera la qualité et dirigera les accouplements sélectifs à grande échelle pour une augmentation de capacité prévue de 10 fois. L'entreprise vise à produire de la soie d'araignée à l'échelle du tonnage métrique et à consolider sa position dans la production de soie d'araignée rentable et respectueuse de l'environnement. Le PDG Kim Thompson déclare que 2024 est une année charnière pour Kraig Labs, avec une expansion continue de la production des hybrides BAM-1.
Kraig Biocraft Laboratories (OTCQB: KBLB) gibt die Rückkehr des renommierten Seidenbau-Experten Dr. Nirmal Kumar bekannt, der die Fertigstellung des zweiten Produktionszyklus der BAM-1 Spinnenseiden-Hybriden überwachen wird. Dieser Zyklus baut auf dem Erfolg des ersten Produktionszyklus auf, der im Juli 2024 abgeschlossen wurde. Dr. Kumar wird die Kokonproduktion überwachen, die Qualität kontrollieren und großflächige selektive Paarungen für eine geplante Steigerung der Kapazität um das 10-fache leiten. Das Unternehmen hat zum Ziel, Spinnenseide auf metrischer Tonnage-Ebene zu produzieren und seine Position in der kosteneffizienten, umweltbewussten Spinnenseiden-Produktion zu festigen. CEO Kim Thompson erklärt, dass 2024 ein Durchbruchsjahr für Kraig Labs sein wird, mit einer fortlaufenden Expansion der BAM-1 Produktionshybriden.
- Second production cycle of BAM-1 spider silk hybrids underway
- Renowned expert Dr. Nirmal Kumar rejoins to oversee operations
- Planning for 10X increase in production capacity
- Aiming for metric-ton level spider silk production
- None.
Renowned Sericulture Expert, Dr. Nirmal Kumar, Rejoins Team to Oversee Operations
ANN ARBOR, Mich., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), announces today that renowned sericulture expert, Dr. Nirmal Kumar, will rejoin the Company's team in Asia to oversee completion of the second production cycle of BAM-1 spider silk hybrids.
Dr. Nirmal Kumar rejoins the team this week, as Kraig Labs prepares to cocoon and reel the second BAM-1 hybrid spider silk production batch. This production cycle will build on the success of the first production cycle completed in July. The recombinant spider silk generated from this production batch will be available for sale and use in end-market product development.
This production cycle is the second of many scheduled for this year as Kraig Labs continues the expansion of its BAM-1 production hybrids.
The production team leaders and Dr. Nirmal Kumar have remained in close daily communications over the last month, laying the groundwork and preparing the facilities for the BAM-1 hybrids, now in production. While in-person with the team, Dr. Nirmal Kumar will supervise the cocoon production and monitor cocoon quality and reeling characteristics. Dr. Nirmal Kumar will also lead and train the team in large-scale selective matings in preparation for a 10X increase in capacity as the rainy season concludes.
During this trip, Dr. Nirmal Kumar will also review the teams' progress in building the facilities, staffing, and equipment necessary to sustain the Company's growing operations and meet its metric-ton level spider silk production target.
"The BAM-1 hybrids, in production now, continue to show the same robustness and performance demonstrated in the spring production trials. Dr. Nirmal Kumar and our team have laid a strong foundation for the massive scale-up in spider silk production, which is now underway. I am very happy to have Dr. Nirmal Kumar rejoin our production team in person as we enter this exciting phase of the rearing cycle. 2024 has been, and will continue to be a breakout year for Kraig Labs," said Company Founder and CEO, Kim Thompson. "The completion of this second production cycle for BAM-1 hybrids will solidify our production model and reaffirm our industry-leading position in cost-effective and eco-responsible spider silk production."
To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com
FAQ
What is the current status of Kraig Biocraft Laboratories' BAM-1 spider silk production?
Who is overseeing the BAM-1 spider silk production for KBLB?
What are Kraig Biocraft Laboratories' (KBLB) production goals for spider silk?
How does Kraig Biocraft Laboratories (KBLB) plan to expand its spider silk production?
